Form 8-K - Current report:
SEC Accession No. 0001104659-24-106676
Filing Date
2024-10-07
Accepted
2024-10-07 16:13:08
Documents
15
Period of Report
2024-10-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2425668d1_8k.htm   iXBRL 8-K 33827
2 EXHIBIT 99.1 tm2425668d1_ex99-1.htm EX-99.1 11493
6 GRAPHIC tm2425668d1_ex99-1img001.jpg GRAPHIC 4096
  Complete submission text file 0001104659-24-106676.txt   232537

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bdtx-20241007.xsd EX-101.SCH 3063
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bdtx-20241007_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bdtx-20241007_pre.xml EX-101.PRE 22391
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2425668d1_8k_htm.xml XML 3696
Mailing Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 617-417-5868
Black Diamond Therapeutics, Inc. (Filer) CIK: 0001701541 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39200 | Film No.: 241357998
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)